94 related articles for article (PubMed ID: 10910068)
1. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer.
Kawano K; Gomi S; Tanaka K; Tsuda N; Kamura T; Itoh K; Yamada A
Cancer Res; 2000 Jul; 60(13):3550-8. PubMed ID: 10910068
[TBL] [Abstract][Full Text] [Related]
2. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.
Nishizaka S; Gomi S; Harada K; Oizumi K; Itoh K; Shichijo S
Cancer Res; 2000 Sep; 60(17):4830-7. PubMed ID: 10987294
[TBL] [Abstract][Full Text] [Related]
3. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
[TBL] [Abstract][Full Text] [Related]
4. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
[TBL] [Abstract][Full Text] [Related]
5. Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes.
Yamada A; Kawano K; Koga M; Takamori S; Nakagawa M; Itoh K
Cancer Res; 2003 Jun; 63(11):2829-35. PubMed ID: 12782588
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
7. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
[TBL] [Abstract][Full Text] [Related]
8. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
[TBL] [Abstract][Full Text] [Related]
9. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
10. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
11. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
12. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
[TBL] [Abstract][Full Text] [Related]
13. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma.
Fukuyama T; Hanagiri T; Takenoyama M; Ichiki Y; Mizukami M; So T; Sugaya M; So T; Sugio K; Yasumoto K
Cancer Res; 2006 May; 66(9):4922-8. PubMed ID: 16651449
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
[TBL] [Abstract][Full Text] [Related]
15. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K
Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737
[TBL] [Abstract][Full Text] [Related]
16. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.
Jin M; Komohara Y; Shichijo S; Harada M; Yamanaka R; Miyamoto S; Nikawa J; Itoh K; Yamada A
Oncol Rep; 2008 May; 19(5):1277-83. PubMed ID: 18425388
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
18. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
19. Establishment of shared antigen reactive cytotoxic T lymphocyte using co-stimulatory molecule introduced autologous cancer cells.
Hirohashi Y; Torigoe T; Hirai I; Tamura Y; Nakatsugawa M; Inoue Y; Kanaseki T; Kamiguchi K; Ikeda H; Sasaki A; Yamanaka N; Sato N
Exp Mol Pathol; 2010 Feb; 88(1):128-32. PubMed ID: 19818766
[TBL] [Abstract][Full Text] [Related]
20. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
